RET
RET fusions in NSCLC and thyroid cancers. Targeted by selpercatinib and pralsetinib.
No Treatments found for this biomarker.
RET fusions in NSCLC and thyroid cancers. Targeted by selpercatinib and pralsetinib.
No Treatments found for this biomarker.